Comprehensive Genomic Profiling (CGP) in the U.S. - Executive Director of Genomics, Top 10 Pharma

An executive director of genomics at a top pharma company discussed their use of CGP in cancer clinical trials trials and summarized key requirements for these tools. They currently use CGP for clinical and research purposes but anticipate a shift towards whole exome sequencing in the future. The stakeholder notes several pain points with CGP, including excessive slide requirements, and they caution that many companies claiming to offer CGP may not deliver due to poor optimization of DNA purification. The stakeholder also discusses their experience with different companies offering CGP as well as their negative experiences with some large CROs. Overall, the stakeholder emphasizes the importance of accurate and efficient genomic services and highlights a few companies for their high-quality data and performance. They also discuss potential future changes in CGP testing, such as a shift towards complementary MRD testing and possible partnerships for custom panels and informatics analysis.

‍